Cargando…
Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
PURPOSE: Dosimetric parameters (e.g., mean lung dose (MLD), V20, and V5) can predict radiation pneumonitis (RP). Constraints thereof were formulated before the era of combined immune checkpoint inhibitors (ICIs) and radiotherapy, which could amplify the RP risk. Dosimetric predictors of acute RP (aR...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792763/ https://www.ncbi.nlm.nih.gov/pubmed/35095930 http://dx.doi.org/10.3389/fimmu.2021.828858 |
_version_ | 1784640449818918912 |
---|---|
author | Bi, Jianping Qian, Jing Yang, Dongqin Sun, Lu Lin, Shouyu Li, Ying Xue, Xudong Nie, Tingting Verma, Vivek Han, Guang |
author_facet | Bi, Jianping Qian, Jing Yang, Dongqin Sun, Lu Lin, Shouyu Li, Ying Xue, Xudong Nie, Tingting Verma, Vivek Han, Guang |
author_sort | Bi, Jianping |
collection | PubMed |
description | PURPOSE: Dosimetric parameters (e.g., mean lung dose (MLD), V20, and V5) can predict radiation pneumonitis (RP). Constraints thereof were formulated before the era of combined immune checkpoint inhibitors (ICIs) and radiotherapy, which could amplify the RP risk. Dosimetric predictors of acute RP (aRP) in the context of ICIs are urgently needed because no data exist thus far. METHODS AND MATERIALS: All included patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs, and followed-up at least once. Logistic regression models examined predictors of aRP (including a priori evaluation of MLD, V20, and V5), and their discriminative capacity was assessed by receiver operating characteristic analysis. RESULTS: Median follow-up of the 40 patients was 5.3 months. Cancers were lung (80%) or esophageal (20%). ICIs were PD-1 (85%) or PD-L1 (15%) inhibitors (median 4 cycles). Patients underwent definitive (n=19), consolidative (n=14), or palliative (n=7) radiotherapy; the median equivalent dose in 2 Gy fractions (EQD2) was 60 Gy (IQR, 51.8-64 Gy). Grades 1-5 aRP occurred in 25%, 17.5%, 15%, 2.5%, and 5%, respectively. The only variables associated with any-grade aRP were V20 (p=0.014) and MLD (p=0.026), and only V20 with grade ≥2 aRP (p=0.035). Neither the number of prior ICI cycles nor the delivery of concurrent systemic therapy significantly associated with aRP risk. Graphs were constructed showing the incrementally increasing risk of aRP based on V20 and MLD (continuous variables). CONCLUSIONS: This is the first study illustrating that V20 and MLD may impact aRP in the setting of prior ICIs. However, these data should not be extrapolated to patients without pre-radiotherapy receipt of prior ICIs, or to evaluate the risk of chronic pulmonary effects. If these results are validated by larger studies with more homogeneous populations, the commonly accepted V20/MLD dose constraints could require revision if utilized in the setting of ICIs. |
format | Online Article Text |
id | pubmed-8792763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87927632022-01-28 Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors Bi, Jianping Qian, Jing Yang, Dongqin Sun, Lu Lin, Shouyu Li, Ying Xue, Xudong Nie, Tingting Verma, Vivek Han, Guang Front Immunol Immunology PURPOSE: Dosimetric parameters (e.g., mean lung dose (MLD), V20, and V5) can predict radiation pneumonitis (RP). Constraints thereof were formulated before the era of combined immune checkpoint inhibitors (ICIs) and radiotherapy, which could amplify the RP risk. Dosimetric predictors of acute RP (aRP) in the context of ICIs are urgently needed because no data exist thus far. METHODS AND MATERIALS: All included patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs, and followed-up at least once. Logistic regression models examined predictors of aRP (including a priori evaluation of MLD, V20, and V5), and their discriminative capacity was assessed by receiver operating characteristic analysis. RESULTS: Median follow-up of the 40 patients was 5.3 months. Cancers were lung (80%) or esophageal (20%). ICIs were PD-1 (85%) or PD-L1 (15%) inhibitors (median 4 cycles). Patients underwent definitive (n=19), consolidative (n=14), or palliative (n=7) radiotherapy; the median equivalent dose in 2 Gy fractions (EQD2) was 60 Gy (IQR, 51.8-64 Gy). Grades 1-5 aRP occurred in 25%, 17.5%, 15%, 2.5%, and 5%, respectively. The only variables associated with any-grade aRP were V20 (p=0.014) and MLD (p=0.026), and only V20 with grade ≥2 aRP (p=0.035). Neither the number of prior ICI cycles nor the delivery of concurrent systemic therapy significantly associated with aRP risk. Graphs were constructed showing the incrementally increasing risk of aRP based on V20 and MLD (continuous variables). CONCLUSIONS: This is the first study illustrating that V20 and MLD may impact aRP in the setting of prior ICIs. However, these data should not be extrapolated to patients without pre-radiotherapy receipt of prior ICIs, or to evaluate the risk of chronic pulmonary effects. If these results are validated by larger studies with more homogeneous populations, the commonly accepted V20/MLD dose constraints could require revision if utilized in the setting of ICIs. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8792763/ /pubmed/35095930 http://dx.doi.org/10.3389/fimmu.2021.828858 Text en Copyright © 2022 Bi, Qian, Yang, Sun, Lin, Li, Xue, Nie, Verma and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Bi, Jianping Qian, Jing Yang, Dongqin Sun, Lu Lin, Shouyu Li, Ying Xue, Xudong Nie, Tingting Verma, Vivek Han, Guang Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors |
title | Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors |
title_full | Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors |
title_fullStr | Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors |
title_full_unstemmed | Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors |
title_short | Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors |
title_sort | dosimetric risk factors for acute radiation pneumonitis in patients with prior receipt of immune checkpoint inhibitors |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792763/ https://www.ncbi.nlm.nih.gov/pubmed/35095930 http://dx.doi.org/10.3389/fimmu.2021.828858 |
work_keys_str_mv | AT bijianping dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT qianjing dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT yangdongqin dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT sunlu dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT linshouyu dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT liying dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT xuexudong dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT nietingting dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT vermavivek dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors AT hanguang dosimetricriskfactorsforacuteradiationpneumonitisinpatientswithpriorreceiptofimmunecheckpointinhibitors |